Latest Interferon Stories
ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis,...
Animals, insects, and plants use a variety of sensing mechanisms to detect invading pathogens such as viruses. One complex and effective antiviral defense system they share is based on recognition of double-stranded RNA (dsRNA), often produced when a virus invades a host cell. New information leading to a clearer understanding of the mechanisms underlying viral dsRNA sensing is presented in a comprehensive Review article published in Journal of Interferon & Cytokine Research, a...
RARITAN, N.J., May 13, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease. Hepatitis...
However, Recent Changes in Brazil and Argentina are Expected to Drive a Shift in Treatment of HCV Genotype 1 Infections, According to a New Report From Decision Resources BURLINGTON, Mass., May 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored medical programs to...
NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Association for the Study of the Liver (EASL). A pre-recorded webcast featuring management from Janssen will provide an...
An All-Oral/Interferon-Free Regimen is One of the Great Unmet Needs in Treatment-Naive HCV, According to a New Report from Decision Resources BURLINGTON, Mass., May 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of genotype-1 hepatitis C virus (HCV) patients achieving a sustained virological...
Benefits include improved drug efficiency, reduced pill burden, and lower dosage frequency LONDON, May 1, 2013 /PRNewswire/ -- The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for Hepatitis B and C. New analysis from Frost & Sullivan...
Gilead Sciences Leads the Way in Delivering the First All Oral Treatment for HCV NEW YORK, April 26, 2013 /PRNewswire/ -- Citeline®, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials has just published an exclusive whitepaper examining the current progress towards a remarkable improvement in the medical treatment for HCV. (Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO ) With news of the impending breakthrough in...
BEERSE, Belgium, April 26, 2013 /PRNewswire/ -- - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA (Janssen), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
-- STARTVerso(TM)1 data presented in treatment-naïve patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin1,2 -- Statistically significant viral cure rates achieved versus placebo plus PegIFN/RBV with similar rates of treatment discontinuation -- The majority of patients qualified for shorter treatment duration of 12 weeks faldaprevir/24...
Latest Interferon Reference Libraries
Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...
